Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Dhodapkar, M. V., Alsina, M., Berdeja, J. G., Patel, K. K., Richard, S., Vij, R., Leleu, X., Egan, D. N., Bergsagel, P. L., Reshef, R., Usmani, S. Z., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Eliason, L., Zhong, X., Greggio, C., Tran, S., … Siegel, D. S. (2023). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up. Blood, 142(Supplement 1), 2101–2101. https://doi.org/10.1182/blood-2023-173970
Authors:
Madhav V. Dhodapkar
Melissa Alsina
Jesús G. Berdeja
Krina K. Patel
Shambavi Richard
Ravi Vij
Xavier Leleu
Daniel Egan
P. Leif Bergsagel
Ran Reshef
Saad Z. Usmani
Anna Truppel-Hartmann
Debashree Basudhar
Ethan Thompson
Xirong Zheng
Laurie Eliason
Xiaobo Zhong
Chiara Greggio
Sinhan Tran
Maria Chaudhry
Marlene J. Carrasco-Alfonso
David S. Siegel
Affiliated Authors:
Ran Reshef
Publication Type:
Article
Unique ID:
10.1182/blood-2023-173970
Journal:
Publication Date:
Data Source:
OpenAlex

Record Created: